The advent of immune checkpoint inhibitors (ICI) targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) has transformed the management of advanced melanoma. The gene discussed is CTLA4; the disease is melanoma.